The Study
Liraglutide effects on beta‐cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes
This study gave one group of people a medicine and another group a fake pill, then saw what happened. It found the medicine helped the pancreas make more insulin, but didn't help the body use insulin better. We can say the medicine probably caused the insulin improvement because it was a fair test.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study tested if a drug called liraglutide helps the pancreas release more insulin right after eating, even if people don’t lose much weight.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 567 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this means liraglutide helps the pancreas work better on its own, even if weight loss is small, which could help control blood sugar more directly.
- 2Liraglutide made the pancreas release 3 times more insulin right after eating (497 units more) and improved overall insulin response by 766 units.
- 3Weight dropped by 2.7 kg, but insulin sensitivity didn’t improve.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes
Year
2017
Authors
C. Anholm, Preman Kumarathurai, L. Pedersen, O. Nielsen, O. Kristiansen, M. Fenger, S. Madsbad, A. Sajadieh, S. Haugaard
Related Content
Claims (4)
Liraglutide lowers blood glucose levels after eating and during fasting, and increases insulin sensitivity in people with obesity and prediabetes by directly activating GLP-1 receptors, without relying on weight loss or mechanisms shared with DPP-4 inhibitors or dietary weight loss.
In patients with type 2 diabetes and coronary artery disease, liraglutide improves the disposition index solely by increasing the initial burst of insulin release from beta cells, without altering how the body responds to insulin or how glucose is processed independently of insulin.
In overweight or obese patients with newly diagnosed type 2 diabetes and stable coronary artery disease, adding liraglutide to metformin increases first-phase insulin secretion by about three times and doubles the disposition index, reflecting improved beta-cell function without changes in insulin sensitivity or glucose effectiveness.
In overweight or obese adults with newly diagnosed type 2 diabetes and stable heart disease, adding liraglutide to metformin does not improve how well the body uses insulin or how effectively glucose is processed, even though it causes a small amount of weight loss, and improvements in insulin production by the pancreas happen without changes in insulin sensitivity or glucose effectiveness.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.